Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer: the case report and literature review
Peng-Fei Zhu\textsuperscript{a,b}, Yun-Wang Chen\textsuperscript{b,c}, Ming-Xing Wang\textsuperscript{a,b}, Ya-Ya Deng\textsuperscript{b,c}, Shuang-Yue Pan\textsuperscript{b}, Zhe-Ling Chen\textsuperscript{b} and Liu Yang\textsuperscript{a,b}

Pancreatic cancer is digestive cancer with limited therapeutic options and a poor outcome. Pancreatic cancer has a high mortality rate, with a 5-year survival rate of less than 5%. The median survival after metastasis of the disease is less than 6 months. Studies have revealed that the standard treatment, including palliative chemotherapy or immunotherapy, is not significantly effective for pancreatic cancer. Herein, we report a case of pancreatic cancer who benefited from a combination of anti-PD-1 immunotherapy and chemotherapy. 

Keywords: case report, chemotherapy, immunotherapy, pancreatic cancer, PD-1, tumor mutational burden

Introduction
Pancreatic cancer is one of the most malignant tumor diseases in the digestive system. According to global cancer statistics in 2018, pancreatic cancer mortality ranks seventh [1]. Patients diagnosed with pancreatic cancer may present with atypical clinical symptoms, and nearly 50% of patients were diagnosed at an advanced stage [2]. The clinical manifestations of pancreatic cancer are not specific, and there is no more accurate direct examination method. Therefore, early diagnosis is difficult. When symptoms such as abdominal pain, jaundice, anorexia and weight loss appear, it is basically in the advanced stage, and the opportunity for radical surgery is lost. Pancreatic cancer therapy remains a formidable challenge and the limited treatment options lead to a dismal 5-year survival rate ranged only from 3 to 15% [3]. The treatment of pancreatic cancer includes surgery, chemotherapy, radiotherapy and interventional therapy. Radical surgery is the only possible cure for pancreatic cancer so far. However, as mentioned above, most patients lose the opportunity for surgery when they are diagnosed [4]. According to the survey, 90% of patients relapse and die after potentially curative surgery without additional treatment [5]. Of course, radiotherapy and chemotherapy are also essential in pancreatic cancer. According to the 2020 American Society of Clinical Oncology guideline update, the first-line chemotherapy regimens for pancreatic cancer include FOLFIRINOX and Gemcitabine plus nab-paclitaxel [6].

In recent years, immunotherapy has made considerable progress in the treatment of cancer. Most importantly, immune checkpoint inhibitors, such as programmed cell death/programmed cell death ligand 1 (PD-1/PD-L1), have made dramatic breakthroughs in the therapy of multiple solid tumors [7–9]. In terms of survival time, PD-1 combined with chemotherapy has more significant overall survival (OS) and progression-free survival (PFS) than other small-molecule tyrosine kinase inhibitors (TKIs) [10–13]. Due to the particularity of pancreatic cancer tumor microenvironment, immune checkpoint inhibitors do not get satisfactory efficacy [14]. To find the advantageous population of immunotherapy, finding the predictors and biomarkers of immunotherapy has become a clinical hotspot. Potential indicators that can predict response to treatment including PD-L1 expression, tumor-mutation burden (TMB), microsatellite instability (MSI) and mismatch repair deficiency (dMMR) [15,16]. However, it is still not clear how to screen out the advantageous population for immunotherapy of pancreatic cancer. Herein, we reported a patient who was diagnosed with pancreatic cancer with a high TMB and lower expression of PD-L1. Patients with pembrolizumab and chemotherapy had a PFS of 9 months and an OS of more than 2 years.

Case report
The 61-year-old male patient was diagnosed with pancreatic malignancy in our hospital in January 2018. When the tumor was first detected in January 2018, laparoscopic radical anterograde modular pancreatosplenectomy was performed immediately. The patient had a history of type 2 diabetes and was treated with long-term insulin control of blood glucose. The patient had no history of drinking or smoking.

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
smoking. He had no family history of cancer. The patient's temperature was 36.9 °C, heart rate was 83 bpm, respiratory rate was 19 breath/min, blood pressure was 130/77 mmHg and oxygen saturation in room air was 98%. There was a palpable hard mass in the left lower abdomen without hepatosplenomegaly. No ascites or edema was observed. Intraoperative pathology revealed cancer cells. It had infiltrated fatty tissue, lymph nodes, and nerves around the pancreas. Pathological genetic tests showed changes in TP53 and KRAS genes. Immune results were PD-L1(-), TMB-H, MMR (p-MMR), MSI (microsatellite stable) (Fig. 1). Immunohistochemical staining results: tumor cells CK7 (+) and CK20 (-), (-), CDX2 Muc - 1 (-) and Ki67 (about 5%), Muc - 2 (+) oven, Muc - 5 ac (+) oven, CD34 (-), CK19 were (+), CA19-9 (+) and CEA (-), SYN (+), CgA (-), CD56 (-). (Fig. 2). Postoperative paclitaxel plus gemcitabine were selected as the adjuvant chemotherapy regimen. Four courses of chemotherapy were performed from 30 January 2018 to 1 March 2018. Unfortunately, the patient developed disease progression in June 2018 (Fig. 3). As a result, clinicians had to switch patients to FOLFIRINOX (oxaliplatin, irinotecan, leucovorin and fluorouracil) combined with nivolumab. Fortunately, after eight cycles of chemotherapy combined with immunotherapy, the patient did not progress and the PFS reached 9 months (Fig. 4). However, the patient eventually developed chemotherapeutic resistance and the immune-related adverse effects occurred. The rash and mucositis were rated to grade 3 adverse effects and we had to stop the immunotherapy regimen. In addition, we subsequently tried again intermittent use of PD-1 in combination with albupacaxel, and to our surprise, the patient continued to benefit from the treatment. But, before long, the patient experienced severe immune side effects again. We had to give up this treatment because the patient could not tolerate it. Finally, we changed different treatment regimens, including other chemotherapy regimens and immunotherapy, and also tried the peptide vaccine, but the treatment effect was not very good. And the patient died in January 2020.

Fig. 1

Analysis of immunotherapy results.
Discussion
As far as we know, this is the first case report of successful treatment of PD-1-negative and TMB-H advanced pancreatic cancer by combining immunotherapy and chemotherapy. This means that TMB has important guiding significance in the immunotherapy of pancreatic cancer. Immunotherapy combined with chemotherapy may become a new option for the treatment of advanced pancreatic cancer. Tumor immunotherapy is a hot topic at present. In recent years, as an important drug in tumor immunotherapy, PD-1/PD-L1 mAb has made great progress in the treatment of solid tumors. However, its application in the treatment of advanced pancreatic cancer has not made much progress. The tumor microenvironment of pancreatic cancer is rich in mesenchymal cells, whose fibrous connective tissue plays an immune barrier role, thus hiding immune targets, which makes it difficult for PD-1/PD-L1 mAb to activate the body’s own immune function and exert its antitumor effect. How to screen the superior population of pancreatic cancer immunotherapy and explore the target of therapeutic effect prediction is one of the clinical hotspots. TMB has been widely studied as a marker for predicting the efficacy of immune checkpoint inhibitors. We report a case of a pancreatic cancer patient with TMB-H who has benefited from immunotherapy. These results suggest that TMB can be used as a prognostic indicator for immunotherapy of pancreatic cancer, which needs to be further studied and translated into clinical practice.

At present, palliative chemotherapy is the first choice for advanced pancreatic cancer. The most commonly used first-line chemotherapy regimens are FOLFIRINOX and Gemcitabine plus nab-paclitaxel [6]. A clinical trial involving 342 patients with pancreatic cancer showed a median PFS of 6.4 months in the FOLFIRINOX group and 3.3 months in the gemcitabine group (hazard ratio for disease progression, 0.47; 95% CI, 0.37–0.59; P<0.001) [17]. Although various chemotherapies have some effect, it is NS in extending the survival time and improving the quality of life of patients [18,19]. In recent years, immunotherapy has made great progress in the treatment of cancer. The current immunotherapy options for pancreatic cancer include PD-1, CTLA-4 inhibitors, oncolytic viruses and so on [6]. New evidence suggests that anti-PD-1 immunotherapy has therapeutic effects on various types of cancer. Especially in glioblastoma, melanoma, anal cancer have obvious antitumor activity [20–22]. In a clinical trial of patients with metastatic nodal cancer, pembrolizumab resulted in significantly longer PFS than chemotherapy [23]. Unfortunately, when PD-1 is used as a single drug, its clinical efficacy in the treatment of PC is limited, which may be partly due to the unique immunosuppressive tumor microenvironment (TME) [24,25]. Studies have shown that the induction of PD-L1/PD-1 blockade by inflammatory factors in the tumor microenvironment may be one of the most important factors affecting the efficacy of PD-L1/PD-1 blockade, including immunoreactive fibronectin-γ, tumor necrosis factor-A, cell growth factors, hypoxia and exosomes [26]. PD-L1 is a transmembrane protein that is considered to be a predictive biomarker for tumor
Treatment timeline of patient.

| Num | Item                        | Result |
|-----|-----------------------------|--------|
| 1   | Tumor mutation Burden, TMB  | 11.7 Muts/Mb |
| 2   | Micro Satellite Instability, MSI | MSS   |
| 3   | MSH1                        | -      |
| 4   | MSH2                        | -      |
| 5   | MSH6                        | -      |
| 6   | PMS2                        | -      |
| 7   | PD-L1 score                 | 0      |
| 8   | Tumor Neoantigens           | 19     |

Analysis of immunotherapy results.

treatment. In this case, we comprehensively analyzed the immunohistochemical in the tumor tissue and found that the PD-L1 expression level was low, but the TMB expression level was high. There is considerable evidence that TMB may be a predictive biomarker of tumor response to immune checkpoint inhibitors (ICIS) in several cancer types [27–29]. TMB is defined as the total number of somatic gene coding errors, base substitutions and gene insertion or deletion errors detected per million bases [29]. TMB can reflect the amounts of mutations in tumor cells. TMB has been proved to be a predictive biomarker of ICIS in MSI-H and MSS tumors. Patients based on TMB-H may better select ICIS patients or potentially expand the candidate pool of immunotherapy. The bridge between TMB and the benefits of immunotherapy may be that new tumor-mutation-specific antigens can be exhibited on the major histocompatibility complex (MHC) on the surface of tumor cells and then identified by tumor-infiltrating T cells. Therefore, higher TMB will generate more new antigens, which can trigger T cells in the tumor, and ICIS enables them to attack and destroy tumor cells [28,30,31]. Since neoantigens are produced by mutations, the higher TMB, the more likely some of the neoantigens presented by MHC proteins to produce immunogenicity, thereby increasing the chance of T cells to recognize and remove cancer cells [32]. It had been demonstrated by investigators that TMB-H was considered to be associated with a better prognosis after ICI treatment [33].

Pancreatic cancer has a very poor prognosis, with a 1-year survival rate of only 24% and a 5-year survival rate of about 4%. Even for resectable pancreatic cancer patients, the 5-year survival rate is only 17% [34]. Most patients are in the advanced stage at the time of treatment and the median survival is only about 6–10 months [35]. Surgery is the only cure for pancreatic cancer, but early diagnosis of pancreatic cancer is difficult. Adjuvant chemotherapy after surgical resection is typically the preferred option to treat early pancreatic cancer. Although FOLFIRINOX and gemcitabine/nab-paclitaxel can improve the prognosis of advanced pancreatic cancer, the development of chemoresistance still leads to poor clinical outcomes. Chemotherapy as adjuvant therapy for pancreatic cancer has also been gradually improved, whereas modified FOLFIRINOX only marginally improved survival [36]. Pancreatic cancer is one of the most chemoresistant cancers [37]. More detailed, TME plays an important role in chemotherapy resistance. In pancreatic cancer, the stroma in the TME constitutes a physical barrier to chemotherapeutic drugs, and an anoxic microenvironment contributes
to chemotherapeutic resistance. In the TME, pancreatic stellate cells cluster with other immune cells and promote chemotherapeutic resistance through different cytokines and signaling pathways [38]. Nevertheless, more pancreatic cancer patients will benefit from precision treatment and targeted drugs [19]. Combination therapy is more effective than immunotherapy alone and can increase the response rate [39]. Immunotherapy combined with chemotherapy in the treatment of many cancers has been proved to be very effective and has achieved satisfactory therapeutic effect [40]. According to a clinical trial: the addition of pembrolizumab to chemotherapy resulted in significantly higher rates of response and longer PFS than chemotherapy alone [41]. Among patients receiving taxanes plus ramucirumab, an obvious higher objective response rate was noticed in the anti-PD-1-exposed group compared with the anti-PD-1-naïve group (60.6 vs. 20.0%) [42]. The PD-1 blockade approach has unique advantages compared to standard therapies. Conventional chemotherapies usually target a specific molecule in the tumor cells. The tumor cells can escape the treatment with mutations of the target molecules, leading to rapid regression. The PD-1 blockade is suitable for a wide range of cancers and provides a long-term response because it triggers an anti-tumor immune system that can target mutated proteins [43]. In the present case, immunohistochemical analysis in the tumor tissue revealed low expression of PD-L1 and high expression of TMB-H, with 11.7 Muts/MB(Fig. 5). The patient’s immunohistochemical results were negative for PD-L1 and positive for tumor load. Furthermore, we found that although the patients had PD-1 side effects in the early stage, the patients could not tolerate PD-1 and the treatment of PD-1 was terminated. However, after our series of antise side effects treatments, when we tried again to use PD-1 in combination with chemotherapy, the patients again benefited from the treatment. It is reasonable to speculate that patients sensitive to immune side effects seem to respond better to PD-1. So, we use chemotherapy combined with immunotherapy to treat pancreatic cancer, obtaining a satisfactory therapeutic effect.

**Conclusion**

Here, we reported a Chinese patient with pancreatic cancer, a high TMB and low expression of PD-L1 who responded well to the combined therapy of pembrolizumab and chemotherapy. In our case, the combination of PD-1 inhibitors and chemotherapy to control pancreatic cancer is a promising treatment approach. The link between TMB and immunotherapy is well demonstrated in this case. And it may lead to a promising combination treatment option for advanced pancreatic cancer with a high TMB.

**Acknowledgements**

The study received informed written consent from all participants. These case studies were based on the principles outlined in the Declaration of Helsinki. The protocol was approved by the ethics committee of the Zhejiang Provincial People’s Hospital. Informed written consent was obtained from the patients for publication of this report and any accompanying images.

P.-F.Z. and Y.-W.C. contributed equally to this work; Z.-L.C. and L.Y. diagnosed the patient; P.-F.Z., Y.-W.C., M.-X.W., Y.-Y.D. and S.-Y.P. analyzed the literature data; All authors wrote and revised the manuscript and issued the final approval for the version to be submitted.

The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *ca Cancer j Clin* 2018; 68:394–424.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *ca Cancer j Clin* 2019; 69:7–33.
3. Pereira SP, Oldfield L, Ney A, Hart PA, Keane MG, Pandol SJ, et al. Early detection of pancreatic cancer. *Lancet Gastroenterol Hepatol* 2020; 5:698–710.
4. Moore A, Donahue T. Pancreatic cancer. *JAMA* 2019; 322:1426.
5. Neoptolemos JP, Kleeff J, Michi P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. *Nat Rev Gastroenterol Hepatol* 2018; 15:333–348.
6. Sohal DPS, Kennedy EB, Cinar P, Grützmann R, Pilarsky C, Yang H, et al. Metastatic pancreatic cancer: ASCO guideline update. *J Clin Oncol* 2020; 38: Jco2001364.
7. Rijnders M, de Wit R, Boomans JL, Lokkema MPJ, van der Veldt AAM. Systematic review of immune checkpoint inhibition in urological cancers. *Eur Urol* 2017; 72:411–423.
8. Lehman JM, Gwin ME, Massion PP. Immunotherapy and targeted therapy for small cell lung cancer: there is hope. *Curr Oncol Rep* 2017; 19:49.
9. Emens LA, Ascariito PA, Darcy PK, Dimaria S, Eggermont AMM, Redmond WL, et al. Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. *Eur J Cancer* 2017; 81:116–129.
10. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet* 2016; 387:1540–1550.
11. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. *JAMA* 2016; 315:1600–1609.
12. Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Getziosino F, Aglietta M, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. *J Clin Oncol* 2018; 36:773–779.
13. Motzer RJ, Nanni NM, McDermott DF, Aron Frontera O, Melichar B, Cheuken TK, et al.; CheckMate 214 Investigators. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. *n Engl J Med* 2018; 378:1277–1290.
14. Fan JQ, Wang MF, Chen HL, Shang D, Das JK, Song J. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma. *Mol Cancer* 2020; 19:32.
15. O’Dwyer TJ, Tansey A, Fong WK, Wang MF, Bouché O, Guimbaud R, Benjamin W, et al.; Group Tumours Digestive of Unicancer, PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *n Engl J Med* 2011; 364:1817–1825.
Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer Zhu et al. e827

18 Sunami Y, Kleeff J. Immunotherapy of pancreatic cancer. Prog Mol Biol Transl Sci 2019; 164:189–216.

19 Zeng S, Pöttler M, Lan B, Grützmann R, Pilsarcsy C, Yang H. Chemoresistance in pancreatic cancer. Int J Mol Sci 2019; 20:4504.

20 Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 2019; 25:477–486.

21 Ribas A, Lawrence D, Atkinson V, Agarwal S, Miller WH Jr, Carlino MS, et al. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat Med 2019; 25:936–940.

22 Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol 2017; 28:1036–1041.

23 André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al.; KEYNOTE-177 Investigators. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. n Engl J Med 2020; 383:2207–2218.

24 Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. KEYNOTE-028 Investigators. Safety and activity of anti-PD-L1 antibody pembrolizumab in patients with advanced cancer. n Engl J Med 2012; 366:2455–2465.

25 Winograd R, Byrne KT, Evans RA, Odorizzi PM, Meyer AR, Bajor DL, et al. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol Res 2015; 3:399–411.

26 Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer 2019; 18:10.

27 Sha D, Jin Z, Budziesz J, Kluck K, Stenzinger A, Sinicrope FA. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov 2020; 10:1806–1825.

28 Ravi NA, Hellmann MD, Snyder A, Krishborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348:124–128.

29 Yarchoan M, Hopkins A, Jaffe EM. Tumor mutational burden and response rate to PD-1 inhibition. n Engl J Med 2017; 377:2500–2501.

30 Chan TA,沃chok JD, Snyder A. Genetic basis for clinical response to CTLA-4 blockade in melanoma. n Engl J Med 2015; 373:1984.

31 Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierio PA, Atmaca A, et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell 2019; 35:329.

32 Chabonon RM, Pedrero M, Lefebvre C, Marabelle A, Soria JC, Postel-Vinay S. Mutational landscape and sensitivity to immune checkpoint blockers. Clin Cancer Res 2016; 22:4309–4321.

33 Samstein RM, Lee CH, Shoushtar AI, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 2019; 51:202–206.

34 Reyes-Gibby CC, Chan W, Abbruzzese JL, Xiong HQ, Ho L, Evans DB, et al. Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation. j Pain Symptom Manage 2007; 34:244–252.

35 Binkley CE, Zhang L, Greenenson JK, Giordano TJ, Kuick R, Misek D, et al. The molecular basis of pancreatic fibrosis: common stromal gene expression in chronic pancreatitis and pancreatic adenocarcinoma. Pancreas 2004; 29:254–263.

36 Conroy T, Hammel P, Hebbard M, Ben Abdelghani M, Wei AC, Raoul JL, et al.; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. n Engl J Med 2018; 379:2395–2406.

37 Adamska A, Elskalani O, Emmanouilidi A, Kim M, Abdul Razak NB, Metharom P, Falasca M. Molecular and cellular mechanisms of chemoresistance in pancreatic cancer. Adv Biol Regul 2018; 68:77–87.

38 Wang S, Li Y, Xing C, Ding C, Zhang H, Chen L, et al. Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer. Am J Cancer Res 2020; 10:1937–1953.

39 Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies targeting the PD-1 signaling pathway. j Biomed Sci 2017; 24:26.

40 Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B, et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer 2017; 17:286–301.

41 Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al.; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. n Engl J Med 2018; 378:2078–2092.

42 Sasaki A, Kawazoe A, Eto T, Okunaka M, Mishima S, Sawada K, et al. Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer. esmo Open 2020; 5:e000775.

43 Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014; 515:577–581.